Could a diabetes pill ease heart failure from amyloid?

NCT ID NCT07240844

First seen Nov 21, 2025 · Last updated May 15, 2026 · Updated 21 times

Summary

This study tests Enavogliflozin, a drug used for diabetes, in 68 adults with amyloid cardiomyopathy—a condition where abnormal proteins stiffen the heart. Participants will take the drug or a placebo for 12 weeks, then switch after a break. The goal is to see if the drug improves heart symptoms and daily function.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYLOID CARDIOMYOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Samsung Medical Center

    Seoul, 06351, South Korea

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Seoul St. Mary's Hospital, The Catholic University of Korea

    Seoul, 06591, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.